ALLO

Company Overview — What Does Allogene Therapeutics, Inc. Do?

Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell ALL. The company also develops ALLO-501, an anti-CD19 allogeneic CAR T cell product candidate that is in Phase I clinical trial for the treatment of R/R non-Hodgkin lymphoma; and ALLO-501A, which is in Phase I/II clinical trial for the treatment R/R large B-cell lymphoma or transformed follicular lymphoma. In addition, it is developing ALLO-715, an allogeneic CAR T cell product candidate that is in a Phase I clinical trial for treating R/R multiple myeloma; ALLO-605, an allogeneic CAR T cell product candidate for the treatment of multiple myeloma; ALLO-647, an anti-CD52 monoclonal antibody; CD70 to treat renal cell cancer; ALLO-819, an allogeneic CAR T cell product candidates for the treatment of acute myeloid leukemia; and DLL3 for the treatment of small cell lung cancer and other aggressive neuroendocrine tumors. The company has license and collaboration agreements with Pfizer Inc.; Servier; Cellectis S.A.; and Notch Therapeutics Inc., as well as clinical trial collaboration agreement with SpringWorks Therapeutics, Inc. It also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of allogeneic CAR T cell product candidates. The company was incorporated in 2017 and is headquartered in South San Francisco, California. Allogene Therapeutics, Inc. (ALLO) is classified as a small-cap stock in the Healthcare sector, specifically within the Pharmaceutical Products industry. The company is led by CEO David D. Chang and employs approximately 310 people. With a market capitalization of $624M, ALLO is one of the notable companies in the Healthcare sector.

Allogene Therapeutics, Inc. (ALLO) Stock Rating — Reduce (April 2026)

As of April 2026, Allogene Therapeutics, Inc. receives a Reduce rating with a composite score of 36.8/100 and 2 out of 5 stars from the Blank Capital Research quantitative model.ALLO ranks #2,554 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, Allogene Therapeutics, Inc. ranks #330 of 838 stocks, placing it in the upper half of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).

ALLO Stock Price and 52-Week Range

Allogene Therapeutics, Inc. (ALLO) currently trades at $3.09. The stock gained $0.18 (6.2%) in the most recent trading session. The 52-week high for ALLO is $2.80, which means the stock is currently trading 10.4% from its annual peak. The 52-week low is $0.86, putting the stock 258.4% above its annual trough. Recent trading volume was 8.4M shares, reflecting moderate market activity.

Is ALLO Overvalued or Undervalued? — Valuation Analysis

Allogene Therapeutics, Inc. (ALLO) carries a value factor score of 16/100 in the Blank Capital model, signaling premium valuation that prices in significant future growth. The price-to-book ratio stands at 2.18x, versus the sector average of 2.75x.

At current multiples, Allogene Therapeutics, Inc. trades at a premium to most Healthcare peers. This elevated valuation may be justified if the company can sustain above-average growth rates and profitability, but it also creates downside risk if earnings disappoint expectations.

Allogene Therapeutics, Inc. Profitability — ROE, Margins, and Quality Score

Allogene Therapeutics, Inc. (ALLO) earns a quality factor score of 23/100, signaling below-average profitability metrics relative to the broader market. The return on equity (ROE) is -74.7%, compared to the Healthcare sector average of -43.5%, which is below typical expectations for high-quality companies. Return on assets (ROA) comes in at -52.5% versus the sector average of -33.1%.

Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.

ALLO Debt, Balance Sheet, and Financial Health

Allogene Therapeutics, Inc. has a debt-to-equity ratio of 42.0%, compared to the Healthcare sector average of 32.0%. The low leverage indicates a conservative balance sheet with significant financial flexibility. The current ratio is 7.93x, indicating strong short-term liquidity. Total debt on the balance sheet is $0. Cash and equivalents stand at $38M.

ALLO has a beta of 1.25, meaning it is more volatile than the broader market — a $10,000 investment in ALLO would be expected to move 25.0% more than the S&P 500 on any given day. The stability factor score for Allogene Therapeutics, Inc. is 26/100, suggesting elevated price swings that may be unsuitable for conservative portfolios.

Allogene Therapeutics, Inc. Revenue and Earnings History — Quarterly Trend

In TTM 2026, Allogene Therapeutics, Inc. reported revenue of $0 and earnings per share (EPS) of $-0.87. Net income for the quarter was $-218M. Operating income came in at $-239M.

In FY 2025, Allogene Therapeutics, Inc. reported revenue of $0 and earnings per share (EPS) of $-0.87. Net income for the quarter was $-191M. Operating income came in at $-209M.

In Q3 2025, Allogene Therapeutics, Inc. reported revenue of $0 and earnings per share (EPS) of $-0.19. Net income for the quarter was $-41M. Operating income came in at $-45M.

In Q2 2025, Allogene Therapeutics, Inc. reported revenue of $0 and earnings per share (EPS) of $-0.23. Net income for the quarter was $-51M. Operating income came in at $-57M.

Over the past 8 quarters, Allogene Therapeutics, Inc. has experienced revenue contraction from $0 to $0. Investors analyzing ALLO stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.

ALLO Dividend Yield and Income Analysis

Allogene Therapeutics, Inc. (ALLO) does not currently pay a dividend. This is common among smaller companies in the Pharmaceutical Products industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.

ALLO Momentum and Technical Analysis Profile

Allogene Therapeutics, Inc. (ALLO) has a momentum factor score of 71/100, indicating strong price momentum with the stock outperforming the majority of the market over recent periods. Stocks with high momentum scores have historically tended to continue their outperformance in the near term. The investment factor score is 25/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 49/100 reflects moderate short selling activity.

ALLO vs Competitors — Healthcare Sector Ranking and Peer Comparison

Within the Healthcare sector, Allogene Therapeutics, Inc. (ALLO) ranks #330 out of 838 stocks based on the Blank Capital composite score. This places ALLO in the upper half of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.

Comparing ALLO against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full ALLO vs S&P 500 (SPY) comparison to assess how Allogene Therapeutics, Inc. stacks up against the broader market across all factor dimensions.

ALLO Next Earnings Date

No upcoming earnings date has been announced for Allogene Therapeutics, Inc. (ALLO) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.

Should You Buy ALLO? — Investment Thesis Summary

The quantitative profile for Allogene Therapeutics, Inc. suggests caution. The quality score of 23/100 flags below-average profitability. The value score of 16/100 indicates premium valuation. Price momentum is positive at 71/100, suggesting the trend favors buyers. High volatility (stability score 26/100) increases portfolio risk.

In summary, Allogene Therapeutics, Inc. (ALLO) earns a Reduce rating with a composite score of 36.8/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on ALLO stock.

Related Resources for ALLO Investors

Explore more research and tools: ALLO vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare ALLO head-to-head with peers: ALLO vs AZN, ALLO vs SLGL, ALLO vs VMD.